Odonate Therapeutics, Inc. Research and Development Expense
Odonate Therapeutics, Inc. reported Research and Development Expense of $2.87 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-11-10
- Odonate Therapeutics, Inc. research and development expense for the quarter ending 2021-09-30 was $2.87M, a 89.84% decline year-over-year.
- Odonate Therapeutics, Inc. research and development expense for the quarter ending 2021-06-30 was $18.63M, a 39.48% decline year-over-year.
- Odonate Therapeutics, Inc. research and development expense for the quarter ending 2021-03-31 was $30.93M, a 10.67% increase year-over-year.
- Odonate Therapeutics, Inc. research and development expense for the quarter ending 2020-12-31 was $30.07M, a 16.33% increase year-over-year.
- Odonate Therapeutics, Inc. research and development expense for fiscal 2020 was $117.04M, a 12.50% increase from fiscal 2019.
- Odonate Therapeutics, Inc. research and development expense for fiscal 2019 was $104.03M, a 30.13% increase from fiscal 2018.
- Odonate Therapeutics, Inc. research and development expense for fiscal 2018 was $79.95M, a 186.53% increase from fiscal 2017.
- Odonate Therapeutics, Inc. research and development expense for fiscal 2017 was $27.90M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2021-09-30 | $2.87M 10-Q · filed 2021-11-10 | $21.49M derived: sum of 2 quarters · filed 2021-11-10 | $52.42M 10-Q · filed 2021-11-10 | $82.50M derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | $18.63M 10-Q · filed 2021-07-27 | $49.55M 10-Q · filed 2021-07-27 | $79.63M derived: sum of 3 quarters · filed 2021-07-27 | $107.87M derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-03-31 | $30.93M 10-Q · filed 2021-05-14 | $61.00M derived: sum of 2 quarters · filed 2021-05-14 | $89.25M derived: sum of 3 quarters · filed 2021-11-10 | $120.02M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-12-31 | $30.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $58.32M derived: sum of 2 quarters · filed 2021-11-10 | $89.09M derived: sum of 3 quarters · filed 2021-11-10 | $117.04M 10-K · filed 2021-02-23 |
| 2020-09-30 | $28.24M 10-Q · filed 2021-11-10 | $59.02M derived: sum of 2 quarters · filed 2021-11-10 | $86.97M 10-Q · filed 2021-11-10 | $112.82M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $30.78M 10-Q · filed 2021-07-27 | $58.72M 10-Q · filed 2021-07-27 | $84.58M derived: sum of 3 quarters · filed 2021-07-27 | $109.67M derived: sum of 4 quarters · filed 2021-07-27 |
| 2020-03-31 | $27.95M 10-Q · filed 2021-05-14 | $53.80M derived: sum of 2 quarters · filed 2021-05-14 | $78.90M derived: sum of 3 quarters · filed 2021-05-14 | $105.35M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $25.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $50.95M derived: sum of 2 quarters · filed 2021-02-23 | $77.40M derived: sum of 3 quarters · filed 2021-02-23 | $104.03M 10-K · filed 2021-02-23 |
| 2019-09-30 | $25.10M 10-Q · filed 2020-10-28 | $51.55M derived: sum of 2 quarters · filed 2020-10-28 | $78.18M 10-Q · filed 2020-10-28 | $104.98M derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $26.45M 10-Q · filed 2020-07-30 | $53.08M 10-Q · filed 2020-07-30 | $79.88M derived: sum of 3 quarters · filed 2020-07-30 | $101.55M derived: sum of 4 quarters · filed 2020-07-30 |
| 2019-03-31 | $26.63M 10-Q · filed 2020-04-28 | $53.43M derived: sum of 2 quarters · filed 2020-04-28 | $75.09M derived: sum of 3 quarters · filed 2020-04-28 | $92.12M derived: sum of 4 quarters · filed 2020-04-28 |
| 2018-12-31 | $26.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $48.46M derived: sum of 2 quarters · filed 2020-02-20 | $65.49M derived: sum of 3 quarters · filed 2020-02-20 | $79.95M 10-K · filed 2020-02-20 |
| 2018-09-30 | $21.67M 10-Q · filed 2019-11-06 | $38.69M derived: sum of 2 quarters · filed 2019-11-06 | $53.15M 10-Q · filed 2019-11-06 | $66.19M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $17.02M 10-Q · filed 2019-07-24 | $31.48M 10-Q · filed 2019-07-24 | $44.52M derived: sum of 3 quarters · filed 2019-07-24 | $53.65M derived: sum of 4 quarters · filed 2019-07-24 |
| 2018-03-31 | $14.46M 10-Q · filed 2019-04-25 | $27.50M derived: sum of 2 quarters · filed 2019-04-25 | $36.63M derived: sum of 3 quarters · filed 2019-04-25 | $39.91M derived: sum of 4 quarters · filed 2019-04-25 |
| 2017-12-31 | $13.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $22.17M derived: sum of 2 quarters · filed 2019-02-22 | $25.45M derived: sum of 3 quarters · filed 2019-02-22 | $27.90M 10-K · filed 2019-02-22 |
| 2017-09-30 | $9.13M 10-Q · filed 2018-10-23 | $12.41M derived: sum of 2 quarters · filed 2018-10-23 | $14.86M 10-Q · filed 2018-10-23 | |
| 2017-06-30 | $3.28M 10-Q · filed 2018-07-30 | $5.74M 10-Q · filed 2018-07-30 | ||
| 2017-03-31 | $2.45M 10-Q · filed 2018-05-03 |